Study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to to assess the objective response rate (ORR) of
sacituzumab govitecan-hziy in adult participants with metastatic solid tumors.